SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Bristol Myers Squibb Presents First Phase 3 Data on KarXT for Alzheimer’s Psychosis

The company presented clinical data from two Phase 3 ADEPT studies evaluating KarXT for psychosis associated with Alzheimer’s disease.

BMY

Related stories